Cooper Pharma

What Cooper Pharma does

Cooper Pharma is a privately held Moroccan pharmaceutical group founded in 1933, headquartered in Casablanca, operating across three continents (Africa, Europe, Middle East) with 1,001-5,000 employees. Its core business spans pharmaceutical manufacturing of branded generic drugs and in-licensed products for approximately 15 multinational partner laboratories (including Pfizer, Merck, Abbott, Daiichi Sankyo, Dr. Reddy's, and Cipla), complemented by an in-house distribution network of 9 centers covering all regions of Morocco. The company holds the #1 position in the Moroccan pharmaceutical market with 9.4% share (IQVIA, 2022). Specialized manufacturing capabilities include solid, liquid, and pasty formulations at the 20,000 sqm Tit Mellil plant (45 million units/year), effervescent tablet production at MC Pharma, contraceptive hormone manufacturing at Gynebio Pharma (launched 2019, first such African site), and incremental R&D in galenic formulations at IDC Pharma. International operations span manufacturing plants in Côte d'Ivoire, Rwanda (Cooper Pharma East Africa, Q4 2021), Saudi Arabia (including Cooper Pharma Arabia and the SPIMACO JV Dammam Pharma), along with offices in the UAE, Spain (EDDA Pharma, Redox Pharma), and the Czech Republic (via Rougier acquisition). Beyond pharma manufacturing and distribution, the group operates Cooper Biosciences focused on biotechnology innovation and biosimilars in the MENA region. Quality and compliance are anchored in GMP (Morocco), AFSSAPS/ANSM (France, 2008), Saudi FDA (2011), UAE Manufacturing Site Registration (2015), and Libyan (2023) certifications, supporting a sales-led go-to-market built around the largest pharmaceutical field sales network in Morocco and abroad, run on a personalized CRM, with marketing supported by medical caravans, social media, and ESG programs covering 50+ foundations in health, education, and environment.

Name

Cooper Pharma

Legal name

Cooper Pharma

Website

https://cooperpharma.ma

Company type

Private

Founded year

1933

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Cooper Pharma is a privately held Moroccan pharmaceutical group founded in 1933 that manufactures and distributes branded generics and in-licensed products across Africa, Europe, and the Middle East, leading the Moroccan market with 9.4% share via 1,001-5,000 employees and 9 domestic distribution centers.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industries

Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD), Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA), Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Pharmaceutical distribution
• Licensed pharmaceuticals
• Contract manufacturing

Headquarters

HQ city

Casablanca

HQ country

Morocco

HQ region

Africa

Offices14 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Manufacturing: Manufacturing of branded generic and innovative drugs compliant with international quality standards. Production of 200+ specialties in nearly 300 presentations. Includes own Cooper-branded generics and originator medicines manufactured for international laboratories.
2. Distribution: Own distribution network of 9 distribution centers covering all regions of Morocco. Reduces delivery times to pharmacies, making medicines accessible to the public.
3. Licensed Product Distribution: Distribution of pharmaceutical products under license from approximately 15 multinational laboratories. Represents about 100 medications under license, complementing own product portfolio.
4. Export: International export activities to Africa, Europe, and Middle East regions, making exports a key lever for international competitiveness and development.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Cooper Pharma manufactures and distributes pharmaceutical products, operating as a producer, distributor, and exporter of branded generic and licensed originator medicines. The company produces 200+ specialties in nearly 300 presentations across major therapeutic areas, complemented by 100+ in-licensed products from approximately 15 multinational partner laboratories. Operations span 6 manufacturing facilities across Africa, Europe, and the Middle East, supported by 9 distribution centers in Morocco and international export activities to 12+ countries.

Product overview

Cooper Pharma is a Moroccan pharmaceutical company offering a dual product portfolio: (1) Cooper-branded generic pharmaceuticals covering over 200 specialities across major therapeutic areas, and (2) licensed pharmaceutical products manufactured or distributed for approximately 15 multinational partner laboratories. The company operates multiple specialized production facilities including Tit Mellil (solid, liquid, pasty products), MC Pharma (effervescent tablets), Gynebio Pharma (contraceptive hormones), IDC Pharma (R&D and incremental development), and CIPLA JV (respiratory/CNS therapies). Distribution is handled through a network of 9 regional centers across Morocco. International operations include Cooper Biosciences for biotech innovation in MENA.

Differentiator

Problem solved

Functional benefit

Products and services

• Cooper Generic Pharmaceuticals Cooper-branded generic pharmaceutical products covering major therapeutic areas with over 100 specialties and totaling 200+ specialties in nearly 300 presentations across the company's portfolio. Distributed through pharmacy networks across Morocco and exported to Africa, Europe, and the Middle East.
• Licensed Partner Pharmaceuticals Pharmaceutical products manufactured or distributed under license from approximately 15 multinational pharmaceutical laboratories including Pfizer, Merck, Abbott Laboratories, Daiichi Sankyo, Pierre Fabre, Almirall, and others. Represents roughly 100 medications covering major therapeutic areas.

Quantifiable outcome

• 9.4% pharmaceutical market share in Morocco (2022) - ranked N°1
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

19 partnerships are on record, tiered core and minor.

• PfizercoreStrategic or Co-development PartnerManufacturing and distribution partnership for pharmaceutical products in Morocco and regional markets
• Mayoly SpindlercoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products
• MerckcoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products
• THEAcoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products
• Abbott LaboratoriescoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products
• Pierre FabrecoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products
• AlmirallcoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products
• Daiichi SankyocoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products
• Dr. Reddy's LaboratoriescoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products
• CiplacoreStrategic or Co-development PartnerJoint venture partnership for respiratory and CNS therapies. Cooper Pharma increased ownership from 15.8% to 24.9% to strengthen leadership position.
• Foundation Mohammed VI for Environmental ProtectionminorStrategic or Co-development PartnerEnvironmental protection partnership through active participation in foundation's projects
• Zakoura Education FoundationminorStrategic or Co-development PartnerEducation sector partnership for early childhood education development in Morocco
• Al Jisr AssociationminorStrategic or Co-development PartnerEducation sector partnership supporting Moroccan educational system development
• Injaz Al MaghribminorStrategic or Co-development PartnerEducation and entrepreneurship initiative partnership in Morocco
• SPIMACOcoreStrategic or Co-development PartnerJoint venture Dammam Pharma with Saudi Arabia's leading pharmaceutical company for new manufacturing plant development
• BiocodexcoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products
• BiofarcoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products
• LALLEMANDcoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products
• Iprad PharmacoreStrategic or Co-development PartnerLicensed manufacturing and distribution partnership for pharmaceutical products

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Cipla: Indian generic pharmaceutical major and Cooper Pharma's JV partner in Cipla Maroc. Direct comparable in respiratory and CNS therapy focus, branded generic portfolio, and emerging markets distribution model.
• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer with manufacturing plants across the MENA region. Comparable to Cooper Pharma in generic manufacturing, in-licensing of international brands, and regional distribution focus.
• Hikma Pharmaceuticals: Jordan-headquartered generic and specialty pharmaceutical manufacturer with a strong MENA and North African footprint. Directly comparable to Cooper Pharma in business model (branded generics + in-licensed products), therapeutic breadth, and regional distribution focus.
• Aspen Pharmacare: South African pharmaceutical group with manufacturing and distribution across sub-Saharan Africa, Europe, and the Middle East. Highly comparable to Cooper Pharma as a regional pharma champion expanding from an African anchor into international markets via acquisition and licensing.
• Dr. Reddy's Laboratories: Indian pharmaceutical company and one of Cooper Pharma's in-licensing partners. Comparable in generic drug manufacturing for global markets, API and finished dosage form production, and emerging markets commercialization strategy.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi Arabia's leading pharmaceutical manufacturer and Cooper's JV partner in Dammam Pharma. Directly comparable in MENA-focused branded generic manufacturing, regional distribution, and partnerships with multinational originators.

Regional players

• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest pharmaceutical manufacturers in Egypt and the MENA region, with a similar portfolio of generics and licensed products. Comparable as a regional pharma manufacturer primarily serving MENA markets, though Egypt-domiciled.

Broad incumbents

• Merck (North Africa/MENA operations): Global pharmaceutical and life sciences company with a North Africa presence and an in-licensing partnership with Cooper Pharma. Broader incumbent competing on originator products while leveraging Cooper for last-mile distribution in selected markets.
• Pfizer (North Africa operations): Global pharmaceutical leader and one of Cooper Pharma's key in-licensing partners. A broad incumbent that supplies Morocco through both direct operations and the Cooper distribution partnership, competing for shelf space and prescriber mind-share.
• Sanofi (North Africa/MENA operations): Global pharmaceutical major with a significant North Africa and MENA presence, including local manufacturing and distribution partnerships. Broader incumbent that competes with Cooper across both originator and generic segments, with much larger scale and pipeline depth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/CooperPharma
• LinkedInlinkedin.com/company/cooper-pharma-ksa

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cooper Pharma